Jean-Philippe Tripet

Aravis is a hands-on investment partner. They work closely with their portfolio firms while providing capital and access to their international network of professionals. The firm's investment strategy targets early-stage firms active in biopharmaceutical, medical technology and biotechnology sectors in Europe, North America and Asia. They have a particular focus on cross-border deals and in firms operating in immunology, inflammation, oncology and CNS segments. They also invest in renewable energy businesses in Europe where they believe there are substantial growth opportunities. They concentrate on firms in the development phase which employ mature established energy production technologies, namely wind, hydroelectric or photovoltaic cells. Aravis has experience initiating, financing and structuring complex projects. The firm aims to diligently conduct scientific and technical analysis of potential projects prior to capital commitment. They look for firms which display optimal risk/return profiles. They closely monitor the quality of the science and actively continue with hands-on intervention in challenging situations, aiming to create value through deal structuring in parallel with careful entry valuations.

Functions as a College/University

Operates as a biotech company focused on the research, development and commercialization of ingredients based on nature

Provides social services

Discovers and develops pharmaceutical products

Provides brokerage services

Lombard Odier-IM is an active, research-driven manager which focuses on long-term capital preservation and tailoring their services to their clients' profiles. The firm shares research globally and combines a top-down view with a bottom-up security selection process. Their investment strategy team elaborates and continuously updates macroeconomic forecasts and investment scenarios based on quantitative and technical analysis, resulting in geographical, sectoral and currency allocations. The buy side equity research team tracks a predefined universe of companies worldwide, with a focus on the Swiss market. They also identify promising sectors, regions and themes, assisted by the quantitative research team.